(CSTM) Constellium - Overview
Stock: Rolled, Extruded, Aerospace, Automotive, Packaging
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 48.8% |
| Relative Tail Risk | -9.22% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.98 |
| Alpha | 133.97 |
| Character TTM | |
|---|---|
| Beta | 1.517 |
| Beta Downside | 1.694 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.35% |
| CAGR/Max DD | 0.32 |
Description: CSTM Constellium January 15, 2026
Constellium SE (NYSE:CSTM) designs, manufactures and sells rolled and extruded aluminum products serving aerospace, packaging, automotive, commercial transportation, general industrial, and defense markets. The firm operates through three operating segments: Packaging & Automotive Rolled Products, Aerospace & Transportation, and Automotive Structures & Industry.
The Packaging & Automotive Rolled Products segment produces can-stock, closure stock and foil for beverage, food and flexible-packaging applications, while also supplying automotive body sheets, heat exchangers and battery-foil for electric-vehicle (EV) batteries. The Aerospace & Transportation segment delivers aluminum plate, sheet and extrusions to aerospace, space, commercial-transport and defense customers. The Automotive Structures & Industry segment provides crash-management systems, side-impact beams, battery enclosures and a range of soft- and hard-alloy extrusions for automotive, rail and industrial uses, complemented by downstream services such as pre-machining, surface treatment and R&D.
Constellium sells directly or via distributors across Europe (France, Germany, Czech Republic, UK, Switzerland), North America (U.S.), and Asia (South Korea, China). In FY 2023 the company generated €4.3 billion of revenue with an adjusted EBITDA margin of roughly 9%, reflecting strong demand for lightweight aluminum in EV battery foils and aerospace recovery. A key macro driver is the ongoing push for carbon-neutral transportation, which is boosting aluminum consumption as manufacturers replace steel to meet stricter emissions standards.
For a deeper, data-rich view of Constellium’s valuation dynamics, you might find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 117.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -1.75 > 1.0 |
| NWC/Revenue: 6.54% < 20% (prev 5.75%; Δ 0.78% < -1%) |
| CFO/TA 0.05 > 3% & CFO 267.2m > Net Income 117.6m |
| Net Debt (2.01b) to EBITDA (585.7m): 3.43 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (142.2m) vs 12m ago -3.52% < -2% |
| Gross Margin: 16.04% > 18% (prev 0.10%; Δ 1594 % > 0.5%) |
| Asset Turnover: 154.2% > 50% (prev 151.4%; Δ 2.73% > 0%) |
| Interest Coverage Ratio: 2.78 > 6 (EBITDA TTM 585.7m / Interest Expense TTM 101.1m) |
Altman Z'' 1.25
| A: 0.10 (Total Current Assets 2.35b - Total Current Liabilities 1.84b) / Total Assets 5.38b |
| B: 0.04 (Retained Earnings 240.0m / Total Assets 5.38b) |
| C: 0.06 (EBIT TTM 281.2m / Avg Total Assets 5.07b) |
| D: 0.10 (Book Value of Equity 446.0m / Total Liabilities 4.51b) |
| Altman-Z'' Score: 1.25 = BB |
Beneish M -3.42
| DSRI: 1.28 (Receivables 819.0m/591.0m, Revenue 7.81b/7.21b) |
| GMI: 0.59 (GM 16.04% / 9.52%) |
| AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16) |
| SGI: 1.08 (Revenue 7.81b / 7.21b) |
| TATA: -0.03 (NI 117.6m - CFO 267.2m) / TA 5.38b) |
| Beneish M-Score: -3.42 (Cap -4..+1) = AA |
What is the price of CSTM shares?
Over the past week, the price has changed by +10.10%, over one month by +24.32%, over three months by +60.34% and over the past year by +151.68%.
Is CSTM a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CSTM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.6 | -0.6% |
| Analysts Target Price | 24.6 | -0.6% |
| ValueRay Target Price | 29.2 | 18% |
CSTM Fundamental Data Overview February 07, 2026
P/E Forward = 8.1566
P/S = 0.4332
P/B = 3.8079
P/EG = 0.06
Revenue TTM = 7.81b USD
EBIT TTM = 281.2m USD
EBITDA TTM = 585.7m USD
Long Term Debt = 1.97b USD (from longTermDebt, last quarter)
Short Term Debt = 59.0m USD (from shortTermDebt, last quarter)
Debt = 2.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.01b USD (from netDebt column, last quarter)
Enterprise Value = 5.46b USD (3.45b + Debt 2.13b - CCE 122.0m)
Interest Coverage Ratio = 2.78 (Ebit TTM 281.2m / Interest Expense TTM 101.1m)
EV/FCF = -54.73x (Enterprise Value 5.46b / FCF TTM -99.8m)
FCF Yield = -1.83% (FCF TTM -99.8m / Enterprise Value 5.46b)
FCF Margin = -1.28% (FCF TTM -99.8m / Revenue TTM 7.81b)
Net Margin = 1.50% (Net Income TTM 117.6m / Revenue TTM 7.81b)
Gross Margin = 16.04% ((Revenue TTM 7.81b - Cost of Revenue TTM 6.56b) / Revenue TTM)
Gross Margin QoQ = 14.50% (prev 12.51%)
Tobins Q-Ratio = 1.02 (Enterprise Value 5.46b / Total Assets 5.38b)
Interest Expense / Debt = 1.27% (Interest Expense 27.0m / Debt 2.13b)
Taxrate = 30.16% (38.0m / 126.0m)
NOPAT = 196.4m (EBIT 281.2m * (1 - 30.16%))
Current Ratio = 1.28 (Total Current Assets 2.35b / Total Current Liabilities 1.84b)
Debt / Equity = 2.52 (Debt 2.13b / totalStockholderEquity, last quarter 845.0m)
Debt / EBITDA = 3.43 (Net Debt 2.01b / EBITDA 585.7m)
Debt / FCF = -20.14 (negative FCF - burning cash) (Net Debt 2.01b / FCF TTM -99.8m)
Total Stockholder Equity = 769.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.32% (Net Income 117.6m / Total Assets 5.38b)
RoE = 15.29% (Net Income TTM 117.6m / Total Stockholder Equity 769.0m)
RoCE = 10.25% (EBIT 281.2m / Capital Employed (Equity 769.0m + L.T.Debt 1.97b))
RoIC = 7.16% (NOPAT 196.4m / Invested Capital 2.74b)
WACC = 7.45% (E(3.45b)/V(5.58b) * Re(11.50%) + D(2.13b)/V(5.58b) * Rd(1.27%) * (1-Tc(0.30)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.37%
Fair Price DCF = unknown (Cash Flow -99.8m)
EPS Correlation: -30.67 | EPS CAGR: -36.85% | SUE: -1.26 | # QB: 0
Revenue Correlation: -24.91 | Revenue CAGR: 2.84% | SUE: 0.95 | # QB: 4
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=+0.042 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.58 | Chg30d=+0.197 | Revisions Net=-1 | Growth EPS=+24.4% | Growth Revenue=+8.9%